<SEC-DOCUMENT>0001104659-25-117947.txt : 20251203
<SEC-HEADER>0001104659-25-117947.hdr.sgml : 20251203
<ACCEPTANCE-DATETIME>20251203072112
ACCESSION NUMBER:		0001104659-25-117947
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251203
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251203
DATE AS OF CHANGE:		20251203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CAPRICOR THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001133869
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34058
		FILM NUMBER:		251544993

	BUSINESS ADDRESS:	
		STREET 1:		10865 ROAD TO THE CURE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(310) 358-3200

	MAIL ADDRESS:	
		STREET 1:		10865 ROAD TO THE CURE
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nile Therapeutics, Inc.
		DATE OF NAME CHANGE:	20070920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SMI PRODUCTS INC
		DATE OF NAME CHANGE:	20010206
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>capr-20251203x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.1.0.0 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 12/3/2025 2:00:46 AM -->
<!-- iXBRL Library version: 1.0.9397.4506 -->
<!-- iXBRL Service Job ID: abd62e98-83e6-415f-b80c-9d4277a86fd9 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:capr="http://capricor.com/20251203" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>CAPRICOR THERAPEUTICS, INC._December 3, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:EntityCentralIndexKey" id="Tc_mwh6NTcvK0O82ZDSvTRbJg_1_1">0001133869</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:AmendmentFlag" id="Tc_UY6ONmGtaEStD80zI4x67Q_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="capr-20251203.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133869</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-12-03</xbrli:startDate><xbrli:endDate>2025-12-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_4e9bcb32_951d_4bbd_b616_637bca7879d1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:DocumentType" id="Narr_aGiVS-1vIEerfGvscPWuFA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_G5ltBS9SFkO7WknjoGqeww"><b style="font-weight:bold;">December 3, 2025</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:EntityRegistrantName" id="Narr_6x-AvMgARkK5KAv81R3WqA"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as Specified in its Charter) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_1f2dae61_4096_42f8_b63f_50791ccc1987"></a><a id="Tc_eC_m1wz3xEqWfWaXChX4XA_2_0"></a><a id="Tc_gH_UUtHpmkWgi2954lmAJQ_2_2"></a><a id="Tc_uIi5TyOr_E2B6Cnh05wf7Q_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_idsu69_wW0efQlPvJaRpVA_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:EntityFileNumber" id="Tc_tRhskPhJY02AlS9ZARb31A_1_2"><b style="font-weight:bold;">001-34058</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:EntityTaxIdentificationNumber" id="Tc_BH4vQbdCikuh077IPLcGsQ_1_4"><b style="font-weight:bold;">88-0363465</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:EntityAddressAddressLine1" id="Narr_umOaoTBfK0a3kPUL69JIVQ"><b style="font-weight:bold;">10865 Road to the Cure, Suite 150</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:EntityAddressCityOrTown" id="Narr_CAeQqOeLKU6WWWe0l2YjHQ"><b style="font-weight:bold;">San Diego</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_gaHgZSH7mUqTkPVO0adv4w"><b style="font-weight:bold;">California</b></ix:nonNumeric><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:EntityAddressPostalZipCode" id="Narr_AoqfZGrrBU6kDN9qHLTIzA"><b style="font-weight:bold;">92121</b></ix:nonNumeric><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:CityAreaCode" id="Narr_mKShClQGl0ywqRgoDtmNWA"><b style="font-weight:bold;">858</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:LocalPhoneNumber" id="Narr_pVfkJhfe3Eq9dbajG1lWNA"><b style="font-weight:bold;">727-1755</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_9PxGKb38sU-sTutoRcrk9w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_vBctsFl220yD_0Tbxak8uQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_KKSfRf1YokGeVfmREO7_7g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_lAVroP9FLUGV81-za-2dQw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:324pt;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_Ul5bZFPARUa9zAbol5ti2Q"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="_1c0baf23_d0e6_4cdb_9993_8a8836d58abc"></a><a id="Tc_0LLuQXPYDESEv2bPzjS3sw_1_0"></a><a id="Tc_DLPYRhWxFE2yxqYtraEUUA_1_2"></a><a id="Tc_35rA4YuZwU6o0ZYxC09VUQ_1_4"></a><a id="Tc_mUUmxcvnyEOT8I2sIg0N-w_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;</p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:1.99%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:Security12bTitle" id="Tc_Q-2krpNEZEWXn7Bt0TWReQ_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" name="dei:TradingSymbol" id="Tc_YzRvzMMl8EWkq-i2eKLa_g_2_2">CAPR</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_0rUItuTt7EKebJmNFH5pFw">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'\005b8b\004f53';line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:50.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Item 7.01</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Regulation FD Disclosure. </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:50.25pt;text-align:justify;text-indent:-50.25pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 3, 2025, Capricor Therapeutics, Inc. (the &#8220;Company&#8221;) announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company&#8217;s filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:50.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Item 8.01</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Other Events. </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:50.25pt;text-align:justify;text-indent:-50.25pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As disclosed above, the Company announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial. HOPE-3 is a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating Deramiocel in boys and young men with Duchenne muscular dystrophy. The study randomized 106 participants across 20 leading U.S. clinical sites. Participants received intravenous Deramiocel at 150 million cells per infusion or placebo every three months for a 12-month period. The average age of participants was approximately 15 years and all were on a stable corticosteroid regimen throughout the study. Baseline demographics were well balanced between treatment arms, approximately 90 percent were receiving cardiac medications at baseline, and over 75 percent had diagnosed cardiomyopathy. Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Topline Efficacy Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:33.32%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Endpoint</b></p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% Slowing of Progression</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">3</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Deramiocel vs. Placebo)</b></p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">p-value</b></p></td></tr><tr><td style="vertical-align:top;width:33.32%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Performance of Upper Limb (PUL v2.0) Total Score</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Primary, n=105)</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">54%</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">p=0.029</p></td></tr><tr><td style="vertical-align:top;width:33.32%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Left Ventricular Ejection Fraction (LVEF %)</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">2</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Key Secondary, n=83)</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">91%</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">p=0.041</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#185; n reflects the number of patients in the ITT population with evaluable PUL v2.0 assessments at 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>n reflects the number of patients in the ITT population with centrally reviewed and evaluable cardiac MRI LVEF assessments at 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">3 </sup>Percent slowing is calculated as the treatment difference divided by the placebo change from baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company expects that detailed HOPE-3 results will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal. Concurrently, the Company and its commercial partner, Nippon Shinyaku (U.S. subsidiary, NS Pharma, Inc.) are advancing launch readiness activities aimed to support timely patient access to Deramiocel, pending potential regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Statements in this Current Report on Form 8-K regarding the efficacy, safety, and intended utilization of the Company&#8217;s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; and any other statements about the Company&#8217;s management team&#8217;s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;could,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact the Company&#8217;s business is set forth in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2025, and in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on November 10, 2025. All forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company assumes no obligation to update these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:50.4pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits. &#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(d) Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="capr-20251203xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, titled &#8220;Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy&#8221;, dated December 3, 2025.</span></a></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (formatted as inline XBRL).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CAPRICOR THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;December 3, 2025</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Linda Marb&#225;n, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Linda Marb&#225;n, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt 0pt 0pt 9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>capr-20251203xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 12/3/2025 02:00:45 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="capr-20251203xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:121.2pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy</b><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Statistical significance was achieved in all type 1 error controlled secondary endpoints </i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in Duchenne</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Company plans to submit its response to the Complete Response Letter incorporating HOPE-3 data, following prior alignment with FDA</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Conference call and webcast today at 8:00 a.m. ET</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">SAN DIEGO, </b>Dec. 3, 2025 (GLOBE NEWSWIRE) -- <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capricor Therapeutics</u> (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company&#8217;s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">&#8220;HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function,&#8221; said Linda Marb&#225;n, Ph.D., Chief Executive Officer of Capricor. &#8220;These results reinforce the durable benefits seen in HOPE-2 and its open-label extension, which has continued for over 48 months, and highlight the strength, consistency and reproducibility of Deramiocel&#8217;s clinical profile after more than a decade of rigorous clinical development. We believe these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position us to address the clinical issues in the Complete Response Letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">HOPE-3 is a randomized, double-blind, placebo-controlled, Phase 3 clinical trial evaluating Deramiocel in boys and young men with Duchenne muscular dystrophy. The study randomized 106 participants across 20 leading U.S. clinical sites. Participants received intravenous Deramiocel at 150 million cells per infusion or placebo every three months for a 12-month period. The average age of participants was approximately 15 years, and all were on a stable corticosteroid regimen throughout the study. Baseline demographics were well balanced between treatment arms, approximately 90 percent were receiving cardiac medications at baseline, and over 75 percent had a clinical diagnosis of cardiomyopathy. Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Topline Efficacy Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;width:33.32%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Endpoint</b></p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% Slowing of Progression</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">3</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Deramiocel vs. Placebo)</b></p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">p-value</b></p></td></tr><tr><td style="vertical-align:top;width:33.32%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Performance of Upper Limb (PUL v2.0) Total Score</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Primary, n=105)</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">54%</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">p=0.029</p></td></tr><tr><td style="vertical-align:top;width:33.32%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Left Ventricular Ejection Fraction (LVEF %)</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">2</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Key Secondary, n=83)</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">91%</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt 4.65pt 0pt 4.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">p=0.041</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#185; n reflects the number of patients in the ITT population with evaluable PUL v2.0 assessments at 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><sup style="font-size:6pt;vertical-align:top;">2 </sup>n reflects the number of patients in the ITT population with centrally reviewed and evaluable cardiac MRI LVEF assessments at 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><sup style="font-size:6pt;vertical-align:top;">3 </sup>Percent slowing is calculated as the treatment difference divided by the placebo change from baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">&#8220;We believe the HOPE-3 PUL results show statistically and clinically meaningful and significant treatment effects on both upper limb function and cardiomyopathy,&#8221; said Craig McDonald, M.D., Distinguished Professor of Physical Medicine &amp; </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="capr-20251203xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:121.2pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Rehabilitation and Pediatrics at UC Davis Health, and National PI of the HOPE-3 trial. &#8220;A nearly 54 percent slowing of skeletal muscle disease progression is extraordinary in Duchenne and directly linked to maintaining independence and quality of life in the most severely affected patients with greatest unmet need. The preservation of function reflected in PUL v2.0 translates into real, practical benefits for boys and young men living with this disease, and the effect of Deramiocel on cardiomyopathy will potentially translate to improved long-term survival. The HOPE-3 study is the first-ever Phase 3 trial in a largely non-ambulatory population with DMD to successfully meet its primary endpoint and to support the development of an innovative therapy over many years with this level of impact has been a profound privilege.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">&#8220;The cardiac findings from HOPE-3 represent a significant advance in the management of Duchenne muscular dystrophy cardiomyopathy,&#8221; said Jonathan Soslow, M.D., MSCI, Professor of Pediatrics (Cardiology) at Vanderbilt University Medical Center. &#8220;Cardiomyopathy is the leading cause of mortality in Duchenne, and stabilizing cardiac function has remained a major unmet need. The statistically and clinically significant preservation of left ventricular ejection fraction in patients treated with Deramiocel observed in HOPE-3 underscores the potential of Deramiocel to address one of the most critical aspects of the disease.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Dr. Marb&#225;n continued, &#8220;For families living with Duchenne who are looking for therapies that preserve functional ability, protect the heart and maintain independence, today&#8217;s results provide real momentum and meaningful progress, offering renewed confidence as we work to advance Deramiocel toward potential regulatory approval.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">We expect that detailed HOPE-3 results will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;">Conference Call and Webcast</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">To participate in the conference call, please dial 1-800-717-1738 (Domestic) or 1-646-307-1865 (International) and reference the conference ID: 52151. Participants can use guest dial-in numbers above and be answered by an operator or click the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Call me</u><sup style="font-size:7.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;vertical-align:top;">TM</sup><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> link</u> for instant telephone access to the event. To participate via a webcast, please click <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">here</u>. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company&#8217;s website</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;">About Duchenne Muscular Dystrophy &#160; &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Duchenne Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. There is no cure, and treatment options remain limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;">About Deramiocel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. CDCs have been investigated in more than 250 peer-reviewed scientific publications and administered to over 250 human subjects across multiple clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Deramiocel has received Orphan Drug Designation for the treatment of Duchenne Muscular Dystrophy (DMD) from both the U.S. FDA and the European Medicines Agency (EMA). In addition, it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA, which may qualify Capricor for a Priority Review Voucher upon approval.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="capr-20251203xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:121.2pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;">About the HOPE-3 Phase 3 Trial</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">HOPE-3 is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial consisting of two cohorts evaluating the safety and efficacy of Deramiocel in participants with DMD. Non-ambulatory and ambulatory boys who meet eligibility criteria are randomly assigned to receive either Deramiocel or placebo every 3 months for a total of four doses during the first 12 months of the trial. A total of 106 eligible subjects were randomized in the dual-cohort trial. For more information, please visit ClinicalTrials.gov (<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NCT05126758</u>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;">About Capricor Therapeutics</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel&#8217;s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX&#8482; platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">capricor.com</u>, and follow Capricor on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facebook</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Instagram</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">X</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-style:italic;font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor&#8217;s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; and any other statements about Capricor&#8217;s management team&#8217;s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;could,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor&#8217;s business is set forth in Capricor&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on November 10, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel and the StealthX&#8482; vaccine are investigational candidates and have not been approved for commercial use in any indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">For more information, please contact:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Capricor Media Contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raquel Cona</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">KCSA Strategic Communications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">rcona@kcsa.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">212.896.1204</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="capr-20251203xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:45.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:121.2pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Capricor Company Contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AJ Bergmann, Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">abergmann@capricor.com</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">858.727.1755</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>capr-20251203xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 capr-20251203xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !< /,# 2(  A$! Q$!_\0
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MSO8YZ.,E[5QE9-M:?+>^WR+FF^*9['1_&,VCAY-0:[-Q &MW):$L 944@>8
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M+13$FCD.%=6/L<T^@ HHICS1H<-(JGT)Q0 ^BD!S2T %%-WJ&QN&?3-#2*I
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MS74^-_$/[<'B3Q;8-I7@[P+>6NKW(\M9Y9#.R$_W55!S[D_A7T+\ [+QQ9^
M;8^/;L7&L2'>J%1YD2'HKD=37>VEI80+Y]K#;1J1GS(44 CZBK)E0!277YCA
M>>OTHJ582CR0A;\6$(23YIRN?+_[4WP!U[6=?LOB%X%5G\0V!5Y[6(XDDV_=
M=/4CH5[^]<MI'[=VO:'8BQ\2> +F;6(1L>2&9H [#U1HR0?H:^OVUBR34?L#
M7,:WFP2>46P<$X'\JCFM;6[U)HYM/BE*QAQ<2*C<DD8Q][MUQCFM8UER*%6%
M[;="'3]YRIRM??J?$=GX;^(7[8OC[3M4U_37\/\ @VP;*AU98U7()5-W+NV
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>capr-20251203.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2025 2:00:50 AM-->
<!--Modified on: 12/3/2025 2:00:50 AM-->
<xsd:schema targetNamespace="http://capricor.com/20251203" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:capr="http://capricor.com/20251203">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://capricor.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20251203_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="capr-20251203_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>capr-20251203_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2025 2:00:50 AM-->
<!--Modified on: 12/3/2025 2:00:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>capr-20251203_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/3/2025 2:00:50 AM-->
<!--Modified on: 12/3/2025 2:00:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="capr-20251203.xsd#DocumentDocumentAndEntityInformation" roleURI="http://capricor.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://capricor.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639003240500451040" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639003240500451040" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639003240500451040" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639003240500451040" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639003240500451040" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639003240500451040" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639003240500451040" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639003240500451040" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639003240500451040" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639003240500451040" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639003240500451040" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639003240500451040" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_639003240500451040" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_639003240500451040" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_639003240500451040" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_639003240500451040" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639003240500451040" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639003240500451040" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639003240500451040" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639003240500451040" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639003240500451040" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639003240500451040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639003240500451040" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 03, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  03,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CAPRICOR THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0363465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10865 Road to the Cure, Suite 150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-1755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAPR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001133869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="capr-20251203x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://capricor.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>capr-20251203.xsd</File>
    <File>capr-20251203_lab.xml</File>
    <File>capr-20251203_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="capr-20251203x8k.htm">capr-20251203x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "capr-20251203x8k.htm": {
   "nsprefix": "capr",
   "nsuri": "http://capricor.com/20251203",
   "dts": {
    "schema": {
     "local": [
      "capr-20251203.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "capr-20251203_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "capr-20251203_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "capr-20251203x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://capricor.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20251203x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "capr-20251203x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://capricor.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-25-117947-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-117947-xbrl.zip
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M&]U5Q&>].(*;9TB5!')76K=S9<Q3@:._:'+V)E\$-L^1R_1UN>?6:HBZ=/M
M<(D%^\U&B'Z1L):YWK):/4.,QDO.RJNZ8X@1<E<BK26OMY#^$Z@0A UX'*]8
MOG%+"W0OQ!DA?G7FVH%Z"^L)CVA !66+D;P= 57CG<A_"C)"^XJTM?#UUM1C
M(&I2$'GKSYXPJJ?1\#*?%ZX[Y6 CC+B2OC:DWLKYB.0P35<$KK+EI(N)YE1+
M0EM4;PT](<%*KJ=;SY]-U?N:HJ7J"&*$!95(:\GKK92G@-5[YLDVGO&B6\-!
MNQ%B7V:LE:ZW&-:3X&D3+#%;D))'W$4P(W2O3%S+?XNJ]RDFL)"SXS?@:[&4
MZV*"V;:T["U$&V'&M?SU:[9Z"]\=RX%,$' TE'>DS>^DW(TCG$$^5&&N':BW
M)N[++4&HM@5?(KPH4/Z@W0C%+S/62I>4PAWG^#\JO;N.LQ.&[O[IT?L'4$L#
M!!0    ( *8Z@UNG.@"W[1P  #/)   4    8V%P<BTR,#(U,3(P,W@X:RYH
M=&WM/6ESVLBVW^^OZ.=Y,[&K6"2Q&'"26P1CAW@C@.,D]:JHEM2 8BU8"TM^
M_3NG6P*Q> W8V,.MFALCM5K=9^^SZ?U_1Y9)!LSU#,?^\$Y.2>\(LS5'-^SN
MAW?E9J56>_??C_]Y_S_))#&^?VJ<$MW1 HO9/M%<1GVFDZ'A]TJDY?3[U"9G
MS'4-TR2?7$/OLO 164[!Q"F)))/A5)^H!T\Z=BD:D9*G-ROAQ'A;5M*9M"(I
M.:*4)*F4S9/RV72D>/C44%WJCJ-=P$/PLF*FN)_*YJ3\_.@F<P>&QL@71R6U
MPQ*AJIY76+&0+&18/IF5<YVD6I"T9%'/*OO[M)#OZ$4Q1\\'4 &X;*^D,^/#
M3L_W^Z5T>J2Z9LIC6JKK#-)P@R]W1PR<#!H.AZEA)N6XW;1<+!;3(YPL'%0R
M#?MZ9B2?$L<JDI1)XVT5 !8-UVC?G0S''X;FN"G-L?B;947*1"-'"S//K 'O
M3H;"*W5_=E/A"G)I<7,R=.FV8*"<_GYVVM1ZS*))P_9\:FN311LC/PE FGDR
M IIAPTH88B?MN]3V.HYK41]0"9/*N:142&;DV#S+0777)(J2E)2DG)].<ANX
MY4QLHFBXRSJWHB>?AKMQ(!IW8'("E(_O>XSJ']];S*<$AR?936 ,/NQHCNT#
M<R7]<1] %_[ZL..SD9_F))/^^-XW?)-]K)3KC5KEHD%:GZN-<KUZV:I5F@E2
M.Z^DVH=,8Y;*7)))$*2)]VGQS/NT>*WJZ../[W5C0#Q_;+(/.Q9UNX:=])U^
M*2/U_0-88!INSXS1#:]OTG')=FR& XQ1"6=CKOC3T'5F\S]AP#F(""!+L8&1
MWT  '@8NQT=;5MJ9-BZKW7)B/]R&:@6#FU.EJO2ML]KHLOS=&0]WB$TM?#LS
M2E4;MC&N $1<:M9LG8U.V'B'&/J'G9;6MH:]_'E+&YQ(%P7EYV%ST&JH7[IM
MN2WO?)2 ..5,II OOD_/K'"]"RZ#H-116!Z9M#M9Z.6/_,6Y=>S3:M,_+$B_
M:]E1?O]K6\&%=JCIL84UIF<!#!3'7)#2S/OX'GFXY'&>@T43SM.E'J=8% W)
M2"2D1IZ^$]Y&XOJPXQE6WV1(4.FY.?E/SPE<_HL3=2D$#-_#$P$33<4X&J-?
MAHZ_.P90*]\&6RHB*K6362S./_PQNC0[>Q\ Z.C1+^ ^US\$Y?(1UYF402QD
MHN>F]R;+U&\9&MV)?D<O2<^ *H+K!)#I&,<L<)=%1\FAH8,JE27I[X,^U5$%
M)TW6\4N%5$&97G*-;F]RS?$,Q 2\Q@24##ACQF;53$;=DNKXO8/Y%RP\:8$
MZ#$^.2CLG) "_6BF#FPJV:&688Y+[UJ&Q3QRSH:DX5C4?I<05^!?#T#1>7?
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MX-26A/=H# 0R'MFCHW9AO7D/=Z10/DLP7W4<4Z5 )#Z0:ESO7;F&#W2)'O7
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M0WCJN#+,J7/U 3\4)=:YU;04*_MGQR=7AG K<#K\$^F%.H=&E3#V59?(&'I
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M   1              "  0    !C87!R+3(P,C4Q,C S+GAS9%!+ 0(4 Q0
M   ( *8Z@UO^U4CR9 4  )\[   5              "  2\#  !C87!R+3(P
M,C4Q,C S7VQA8BYX;6Q02P$"% ,4    " "F.H-;9@ 7FV $  "S)0  %0
M            @ '&"   8V%P<BTR,#(U,3(P,U]P<F4N>&UL4$L! A0#%
M  @ ICJ#6Z<Z +?M'   ,\D  !0              ( !60T  &-A<'(M,C R
M-3$R,#-X.&LN:'1M4$L! A0#%     @ ICJ#6]6*"M)-&@  TWL  !@
M         ( !>"H  &-A<'(M,C R-3$R,#-X97@Y.60Q+FAT;5!+!08
.!0 % $T!  #[1      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>capr-20251203x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="capr-20251203.xsd" xlink:type="simple"/>
    <context id="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133869</identifier>
        </entity>
        <period>
            <startDate>2025-12-03</startDate>
            <endDate>2025-12-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Tc_mwh6NTcvK0O82ZDSvTRbJg_1_1">0001133869</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Tc_UY6ONmGtaEStD80zI4x67Q_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_aGiVS-1vIEerfGvscPWuFA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_G5ltBS9SFkO7WknjoGqeww">2025-12-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_6x-AvMgARkK5KAv81R3WqA">CAPRICOR THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Tc_idsu69_wW0efQlPvJaRpVA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Tc_tRhskPhJY02AlS9ZARb31A_1_2">001-34058</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Tc_BH4vQbdCikuh077IPLcGsQ_1_4">88-0363465</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_umOaoTBfK0a3kPUL69JIVQ">10865 Road to the Cure, Suite 150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_CAeQqOeLKU6WWWe0l2YjHQ">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_gaHgZSH7mUqTkPVO0adv4w">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_AoqfZGrrBU6kDN9qHLTIzA">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_mKShClQGl0ywqRgoDtmNWA">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_pVfkJhfe3Eq9dbajG1lWNA">727-1755</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_9PxGKb38sU-sTutoRcrk9w">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_vBctsFl220yD_0Tbxak8uQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_KKSfRf1YokGeVfmREO7_7g">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_lAVroP9FLUGV81-za-2dQw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_Ul5bZFPARUa9zAbol5ti2Q">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Tc_Q-2krpNEZEWXn7Bt0TWReQ_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Tc_YzRvzMMl8EWkq-i2eKLa_g_2_2">CAPR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_12_3_2025_To_12_3_2025_rRbmuvqL2E2pmMIxUAXoyw"
      id="Narr_0rUItuTt7EKebJmNFH5pFw">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
